WX8

WX8 (Ro 91-4714) is an ATP-competitive PIKFYVE inhibitor, with Kd values of 0.9 nM and 340 nM for PIKFYVE and PIP4K2C, respectively. WX8 (Ro 91-4714) inhibits lysosomal fission without effecting homotypic lysosomal fusion. WX8 (Ro 91-4714) is used in the research of autophagy-dependent cancer[1].

Product Specifications

CAS Number

[232935-92-1]

Product Name Alternative

Ro 91-4714

UNSPSC

12352005

Target

PIKfyve

Type

Reference compound

Related Pathways

PI3K/Akt/mTOR

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/wx8.html

Purity

99.43

Solubility

DMSO : 100 mg/mL (ultrasonic)

Smiles

C1(/C=N/NC2=NC(NC3=CC=CC=C3)=NC(N4CCOCC4)=N2)=CNC5=C1C=CC=C5

Molecular Formula

C22H22N8O

Molecular Weight

414.46

References & Citations

[1]Ajit Roy, et al. Selective Termination of Autophagy-Dependent Cancers. Cells. 2024 Jun 25;13 (13) :1096.|[2]Gaurav Sharma, et al. A family of PIKFYVE inhibitors with therapeutic potential against autophagy-dependent cancer cells disrupt multiple events in lysosome homeostasis. Autophagy. 2019 Oct;15 (10) :1694-1718.